Last checked at 31 Aug 2021 16:33
BiVictriX Therapeutics plc
("BiVictriX" or the "Company")
Total Voting Rights
Alderley Park, UK, 31 August 2021: BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces, for the purposes of the FCA's Disclosure and Transparency Rules, that the total issued share capital of the Company consists of 66,115,201 ordinary shares of 1 pence each with voting rights.
The total number of voting rights in the Company is 66,115,201 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in the interest in, the share capital of the Company.
For more information, please contact:
BiVictriX Therapeutics plc |
|
Tiffany Thorn, Chief Executive Officer | Email: info@bivictrix.com |
| |
| |
SP Angel Corporate Finance LLP (NOMAD and Broker) | Tel: +44 (0) 20 3470 0470 |
David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales & Broking)
| |
Consilium Strategic Communications |
|
Ashley Tapp, Priit Piip | Tel: +44 (0) 20 3709 5700 Email: Bivictrix@consilium-comms.com |
|
|